134.25 USD
-3.53 (-2.58%)
AT CLOSE (11:59 AM EDT)
Gilead Sciences Inc (GILD)
NASDAQ: GILD • USD
133.32
-0.94 (-0.70%)
POST MARKET (AS OF 07:52 PM EDT)
Market: CLOSED
Open?$136.85
High?$137.47
Low?$134.10
Prev. Close?$134.25
Volume?5.7M
Avg. Volume?6.6M
VWAP?$135.75
Rel. Volume?0.86x
Bid / Ask
Bid?$129.58 × 100
Ask?$134.24 × 100
Spread?$4.66
Midpoint?$131.91
Valuation & Ratios
Market Cap?166.6B
Shares Out?1.2B
Float?1.2B
Float %?99.7%
P/E Ratio?19.58
P/B Ratio?7.34
EPS?$6.86
Dividend?2.40%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?1.55Adequate
Quick Ratio?1.40Adequate
Cash Ratio?0.64Adequate
Debt/Equity?1.10Moderate
ValuationFAIRLY VALUED
Score67/100
P/E?19.6FAIR▾
P/B?7.34FAIR▾
P/S?5.66FAIR▾
P/FCF?17.6CHEAP▾
EV/EBITDA?12.8FAIR▾
EV/Sales?6.25HIGH▾
Returns & Efficiency
ROE?37.5%STRONG▾
ROA?14.4%STRONG▾
Cash Flow & Enterprise
FCF?$9.5B
Enterprise Value?$184.0B
Related Companies
Loading...
News
Profile
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Employees
17.0K
Market Cap
166.6B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
1992-01-22
Address
333 LAKESIDE DR
FOSTER CITY, CA 94404
Phone: (650) 574-3000
FOSTER CITY, CA 94404
Phone: (650) 574-3000